Aciont, Inc.

Salt Lake City, UT 84103

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $4.85MM
First Award Date 09/10/02
Most Recent Award Date 05/01/14

Key Personnel

Last Name Name Awards Contact
Ghanem Abdel-Halim Ghanem 2
Miller David J Miller 1
Higuchi William I Higuchi 6

9 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 05/01/14 - 04/30/16

DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of intermediate and posterior uveitis has been either oral me...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 05/01/14 - 04/30/15

DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of intermediate and posterior uveitis has been either oral me...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 05/01/13 - 04/30/14

DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of intermediate and posterior uveitis has been either oral me...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/30/10 - 03/29/12

DESCRIPTION (provided by applicant): The overarching aim of this innovative proposal is to develop and then commercialize a non-invasive topical product which is safe and easy to administer that treats severe uveitis, including intermediate and posterior uveitis. Uveitis is the third leading cause of blindness in the United States. Heretofore, t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: RFA-OD-09-009
Budget: 07/01/10 - 06/30/11

DESCRIPTION (provided by applicant): Iontophoresis is a method of using a mild electrical current to enhance the penetration of a drug through tissue. Our long term goal is to develop the Visulex(r) ocular iontophoresis device capable of delivering large molecule anti-VEGF agents to the posterior segment of the eye: * A safe, noninvasive ocula...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/30/09 - 09/29/10

DESCRIPTION (provided by applicant): The overarching aim of this innovative proposal is to develop and then commercialize a non-invasive topical product which is safe and easy to administer that treats severe uveitis, including intermediate and posterior uveitis. Uveitis is the third leading cause of blindness in the United States. Heretofore, t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/04 - 09/29/06

Intermediate and posterior uveitis cause 10% of blindness in the U.S. The mainstay of therapy is to eradicate the infectious cause and to quell the inflammation with corticosteroids or immunosuppressants. Delivery of anti-inflammatory drugs to the posterior portion of the globe in therapeutic concentrations has proven difficult. There are four m...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/20/02 - 09/30/03

DESCRIPTION (provided by applicant): The accurate measurement of blood glucose concentration is important in the management of diabetes. Current methods of glucose monitoring involve piercing the skin and collecting blood samples for analysis up to four times daily or more. Even the non-invasive Glucowatch tm glucose monitoring system requires t...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/10/02 - 08/31/06

DESCRIPTION (provided by applicant): Phenylketonuria (PKU) is a genetic deficiency of phenylalanine hydroxylase (PAH). Without PAH, the patient with PKU cannot metabolize phenylalanine (PHE) to tyrosine. The resulting accumulation of PHE and the accumulation of phenylpyruvate by a secondary metabolic pathway in the patient's blood produce neuro...